London (PRWEB UK) 2 March 2014
New imaging information technology (IT) has been developed to help radiologists improve patient care, streamline workflow, and lower costs. Imaging allows us to answer questions that we did not know the answer to before. For example, it can help determine the composition of the tumour, clinical evaluation of patients and evaluation of new treatments. Imaging within the arena of personalised healthcare is an area of increasing significance and will revolutionise the field of oncology.
Attendees will be given practical tips and guidance on cost-effective imaging management, regulatory insights will be provided and alternatives to costly independent reviews will be discussed. The use of imaging in clinical trials (Phases 2 and 3) will be considered and debated in addition to the use of novel biomarkers.
With just 1 week to go - the event represents an excellent platform in 2014 for learning about the use of imaging pre-clinically and also in clinical trials, giving delegates access to the latest information and key case studies from across the industry.
Hear from key speakers including:
Attending companies include: Janssen, Roche Diagnostics, Novartis, Hoffmann-La Roche, GlaxoSmithKline, Merck KGaA, BioClinica, Lyscaut, Cancer Research UK, TNO, ICON Clinical Research, Asia HealthPartners, Aviesan, Banook Group, Cardiff University, EORTC, European Society of Oncologic Imaging, Imanova, National Institute of Allergy and Infectious Diseases (NIH), UZ Leuven, Edinburgh University and many more.
To view the full speaker line-up and conference programme, visit http://www.smi-online.co.uk/2014cancer-imaging27.asp.
Plus Interactive Pre Conference Workshop
11 March 2014 | 08:30 a.m. - 12:30 p.m.
Host: Dr Marijn Vlaming, Research Scientist, TNO